Skip to main content

Post Reproductive Health

Start: 07/11/2017 08:45
End: 08/11/2017 17:30

Location: RCOG
Programme: Post Reproductive Health 2017.pdf

Joint RCOG/BMS Meeting


This meeting endeavours to provide answers to the most commonly asked and most difficult questions in the management of post reproductive health. These will be put into the context of the Guideline on the Treatment and Management of the Menopause, published in 2015 by the National Institute for Health and Care Excellence (NICE) and the British Menopause Society guidelines on hormone replacement therapy published in 2016.

Nationally and internationally recognised speakers will cover controversial questions in important areas such as:

  • Pathophysiology of the menopause
  • Risks of hormone dependent malignancies
  • Cardiovascular diseases, osteoporosis and cognitive problems
  • Premature ovarian insufficiency: diagnosis and management
  • Lifestyle, complementary therapies, HRT and alternatives for managing the menopause

The meeting will closely follow the recommended syllabus and is suitable for the theoretical component of the BMS/RCOG ‘Menopause’ Advanced Training Skills Module (ATSM) and the Faculty of Sexual and Reproductive Healthcare Advanced Menopause Certificate.

Case studies and breakout workshops will be used to illustrate management principles and develop care pathways for routine and complex menopause related problems.

After completing this course, you will be able to:

  • Recognise the ways in which the menopause can affect quality of life and long term health
  • Target investigations according to each clinical scenario
  • Individualise hormonal and alternative therapeutic regimens that best suit your patient
  • Manage patients with menopause related problems confidently
  • Identify and fully comprehend key research in the field of post-reproductive Health
  • Use the course as the theoretical component of the RCOG ATSM
  • Obtain the BMS/FSRH Advanced Menopause Certificate
  • Claim a maximum of 13 CPD credits for full attendance at the meeting

Who should attend?

  • Trainees in Obstetrics and Gynaecology and in Sexual Health
  • Sub-specialist Trainees in Reproductive Medicine/Community Gynaecology
  • Consultants in Obstetrics and Gynaecology
  • General Practitioners, Practice Nurses and Specialist Nurses
  • Community Gynaecologists

Course Organisers                      

Mr Haitham Hamoda FRCOG, London  

Mr Mike Savvas FRCOG, London                                               

Mr Nick Panay MRCOG, London

Honorary Director of Conferences 

Mr Nick Panay MRCOG, London

Honorary Deputy Director of Conferences 

Mr Philip Toozs-Hobson FRCOG, Birmingham

Course fees

The registration fee (inclusive of online discount and VAT at 20%) for this event is:

  • Standard Rate: £525.00
  • RCOG/Member inc SAS Doctors Rate: £470.00
  • Trainee Rate: £420.00
  • Allied Healthcare Professional Rate: £355.00 

We will automatically allocate you a rate based on the information we hold about you in our database.

How to book

  • Sign into the RCOG website or create your account here – you need to be registered with the RCOG website to book on to an event
  • Check that your card billing address is listed in ‘My account’ > ‘My details’ > ‘Addresses’, as you will need this in order to complete your booking
  • Check that your details are correct in ‘My account’ > ‘My details’ > ‘Career stage’, as we will use this to calculate your registration fee
  • Return to this page
  • Scroll down to the bottom of the page to find the booking form, which will appear once you are logged in 

Alternatively, you can book using the postal booking form (PDF, 601 kb) although if you book using this method you will not receive the online discount. 

If you would like your hospital or trust to be invoiced for your place, please read the events FAQs for further details.

For any queries regarding this event, please contact Karen Collings:

Kora Healthcare

Kora Healthcare launches new Regelle, a Long Lasting Vaginal Moisturiser. One application of Regelle lasts three days and it is a water-based intravaginal gel providing soothing, continuous moisture and relief from symptoms of vaginal dryness, atrophy, itching, irritation and discomfort.

Regelle is a NON-hormonal preparation and can be used in conjunction with anti-oestrogens. Regelle comes in pre-filled applicators:  3 pack (9 days’ supply), 6 pack (18 days’ supply) and 12 pack (36 days’ supply) and is available on NHS prescription as well as Over the Counter (OTC) from all UK pharmacies.

Regelle is Kora’s latest addition to a range that includes Relactagel our non-antibiotic treatment for BV (Bacterial Vaginosis) which is also available as a prescription or OTC.

the yes yes company


The Yes Yes Company

In 2006 The Yes Yes Company launched a range of innovative certified organic non- hormonal vaginal moisturisers and lubricants for use by women suffering from menopausal vaginal atrophy, dyspareunia and vulval disorders. Glycerine & paraben free, pH balanced and with a low osmolality range, YES is designed to be side-effect free, non-irritating and can be used in harmony with systemic and topical HRT especially when low dose vaginal oestrogen does not provide sufficient relief from symptoms.

Recommended by leading Health Care Professionals YES VM Vaginal Moisturising Gel and Yes water-based Intimate Lubricant in pre-filled applicators or tubes are available on prescription, and a wider range of products can be purchased OTC from YES products offer a cost effective natural alternative to existing vaginal moisturisers. 



Mylan ranks among the leading global generic and specialty pharmaceutical companies. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.

In the UK, Mylan has one of the largest portfolio of generic and branded generic drugs, offering an extensive range of dosage forms and delivery systems. At Mylan we have one global quality standard in everything we do. Our internal teams conduct reviews of all products, start to finish. No matter where in the world they are made.

Why such high standards? Because we truly care about the people who will be helped by the medicines we make. And we believe in earning that trust from physicians, pharmacists, other health care professionals and patients, every day. This is why we say, “Our Mylan is Your Mylan.”


Cynosurecyno+hologicmona lisa touch

Cynosure, a Hologic Company, is a leading developer and manufacturer of a broad array of light-based aesthetic and medical treatment systems. Our products are used to provide a diverse range of treatment applications. One such product is The MonaLisa Touch which is an innovative laser procedure, designed and produced by DEKA (Italy), that delivers fractional CO2 laser energy to the vaginal wall tissue for the treatment of Vaginal Atrophy, particularly those that are not able to tolerate topical oestrogens. The procedure is performed in an outpatient environment without the need for anaesthesia and with virtually no pain or side effects.


Besins Healthcarebesins

Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.

Over the last 30 years, Besins has established a strong and reputable name in the production of drugs for the treatment of gynaecological, fertility and obstetrical conditions as well as androgen deficiency and has become a renowned player in the area of hormonal therapies.

Besins global commercial operations is based in the UK and our drugs are distributed in more than 90 countries via subsidiary companies (Besins affiliates) as well as a network of business partners. Besins is actively pursuing new growth opportunities through acquisition and expansion into new territories, bringing significant growth over the coming years.

Besins products are manufactured in a number of countries including France, Belgium and Spain.

To ensure we meet the needs of tomorrow, Besins has two primary research and development facilities across the globe. The research of the group is managed/handled by BHR Pharma, USA, which is an affiliate of Ascend Therapeutics, Inc.

You need to be logged in to the RCOG website to make an online booking. Please go to the log-in page.